Axonal transport defects in neurodegenerative diseases

Journal of Neuroscience

Volumn 29, Issue 41, 2009, Pages 12776-12786

  Morfini, Gerardo A ^a   Burns, Matthew ^a   Binder, Lester I ^b   Kanaan, Nicholas M ^b   Lapointe, Nichole ^b   Bosco, Daryl A ^c   Brown Jr , Robert H ^c   Brown, Hannah ^d   Tiwari, Ashutosh ^e   Hayward, Lawrence ^c   Edgar, Julia ^f   Nave, Klaus Armin ^g   Garberrn, James ^h   Atagi, Yuka ^a   Song, Yuyu ^a   Pigino, Gustavo ^a   Brady, Scott T ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e MICHIGAN TECHNOLOGICAL UNIVERSITY   (United States)

^f UNIVERSITY OF GLASGOW   (United Kingdom)

^g MAX PLANCK INSTITUTE OF EXPERIMENTAL MEDICINE   (Germany)

^h WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; TAU PROTEIN; MICROTUBULE ASSOCIATED PROTEIN;

ADULT ONSET NEURODEGENERATIVE DISEASE; ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; APOPTOSIS; AXONAL INJURY; BRAIN TISSUE; CELL LOSS; CONFERENCE PAPER; DEGENERATIVE DISEASE; GENE EXPRESSION; HEREDITARY MOTOR SENSORY NEUROPATHY; HUMAN; HUNTINGTON CHOREA; MOTOR NEURON DISEASE; NERVE CELL; NERVE FIBER TRANSPORT; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; REGULATORY MECHANISM; SYNAPTIC POTENTIAL; ANIMAL; BIOLOGICAL MODEL; DISEASE MODEL; GENETICS; METABOLISM; MOUSE; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW; SIGNAL TRANSDUCTION; SYNAPSE;

AMYLOID BETA-PROTEIN; ANIMALS; AXONAL TRANSPORT; DISEASE MODELS, ANIMAL; HUMANS; MICE; MICROTUBULE-ASSOCIATED PROTEINS; MODELS, BIOLOGICAL; NEURODEGENERATIVE DISEASES; NEURONS; SIGNAL TRANSDUCTION; SYNAPSES; TAU PROTEINS;

EID: 70350455072     PISSN: 02706474     EISSN: 15292401     Source Type: Journal    
DOI: 10.1523/JNEUROSCI.3463-09.2009     Document Type: Conference Paper

References (125)

1. Ackerley S, Grierson AJ, Banner S, Perkinton MS, Brownlees J, Byers HL, Ward M, Thornhill P, Hussain K, Waby JS, Anderton BH, Cooper JD, Dingwall C, Leigh PN, Shaw CE, Miller CC (2004) p38alpha stress-activated protein kinase phosphorylates neurofilaments and is associated with neurofilament pathology in amyotrophic lateral sclerosis. Mol Cell Neurosci 26:354-364. (Pubitemid 38781091)
2. Albin RL, Reiner A, Anderson KD, Dure LS 4th, Handelin B, Balfour R, Whetsell WO Jr, Penney JB, Young AB (1992) Preferential loss of striato-external pallidal projection neurons in presymptomatic Huntington's disease. Ann Neurol 31:425-430.
3. Andersen JK, Kumar J, Srinivas B, Kaur D, Hsu M, Rajagopalan S (2001) The hunt for a cure for Parkinson's disease. Sci Aging Knowledge Environ 2001:re1.
4. Baas PW, Karabay A, Qiang L (2005) Microtubules cut and run. Trends Cell Biol 15:518-524.
5. Bendotti C, Atzori C, Piva R, Tortarolo M, Strong MJ, DeBiasi S, Migheli A (2004) Activated p38MAPK is a novel component of the intracellular inclusions found in human amyotrophic lateral sclerosis and mutant SOD1 transgenic mice. J Neuropathol Exp Neurol 63:113-119. (Pubitemid 38174776)
6. Binder LI, Frankfurter A, Rebhun LI (1985) The distribution of tau in the mammalian central nervous system. J Cell Biol 101:1371-1378. (Pubitemid 16203754)
7. Binder LI, Guillozet-Bongaarts AL, Garcia-Sierra F, Berry RW (2005) Tau, tangles, and Alzheimer's disease. Biochim Biophys Acta 1739:216-223.
8. Björkblom B, Vainio JC, Hongisto V, Herdegen T, Courtney MJ, Coffey ET (2008) All JNKs can kill, but nuclear localization is critical for neuronal death. J Biol Chem 283:19704-19713.
9. Boison D, Stoffel W (1994) Disruption of the compacted myelin sheath of axons of the central nervous system in proteolipid protein-deficient mice. Proc Natl Acad Sci U S A 91:11709-11713. (Pubitemid 24356414)
10. Bossy-Wetzel E, Schwarzenbacher R, Lipton SA (2004) Molecular pathways to neurodegeneration. Nat Med 10 [Suppl]:S2-S9.
11. Brady ST, Pfister KK, Leopold PL, Bloom GS (1990) Fast axonal transport in isolated axoplasm. Cell Motil Cytoskeleton 17 [Video Suppl 2]:22.
12. Brill LB 2nd, Pfister KK (2000) Biochemical and molecular analysis of the mammalian cytoplasmic dynein intermediate chain. Methods 22:307-316.
13. Brinkman RR, Mezei MM, Theilmann J, Almqvist E, Hayden MR (1997) The likelihood of being affected with Huntington disease by a particular age, for a specific CAG size. Am J Hum Genet 60:1202-1210. (Pubitemid 27194105)
14. Bruijn LI, Houseweart MK, Kato S, Anderson KL, Anderson SD, Ohama E, Reaume AG, Scott RW, Cleveland DW (1998) Aggregation and motor neuron toxicity of an ALS-linked SOD1 mutant independent from wildtype SOD1. Science 281:1851-1854. (Pubitemid 28450505)
15. Bruijn LI, Miller TM, Cleveland DW (2004) Unraveling the mechanisms involved in motor neuron degeneration in ALS. Annu Rev Neurosci 27:723-749.
16. Carmel G, Mager EM, Binder LI, Kuret J (1996) The structural basis of monoclonal antibody Alz50's selectivity for Alzheimer's disease pathology. J Biol Chem 271:32789-32795. (Pubitemid 27008707)
17. Chen XJ, Levedakou EN, Millen KJ, Wollmann RL, Soliven B, Popko B (2007) Proprioceptive sensory neuropathy in mice with a mutation in the cytoplasmic dynein heavy chain 1 gene. J Neurosci 27:14515-14524.
18. Coleman M (2005) Axon degeneration mechanisms: commonality amid diversity. Nat Rev Neurosci 6:889-898.
19. Coleman MP, Perry VH (2002) Axon pathology in neurological disease: a neglected therapeutic target. Trends Neurosci 25:532-537.
20. Collard JF, Côté F, Julien JP (1995) Defective axonal transport in a transgenic mouse model of amyotrophic lateral sclerosis. Nature 375:61-64.
21. Conde C, Cáceres A (2009) Microtubule assembly, organization and dynamics in axons and dendrites. Nat Rev Neurosci 10:319-332.
22. Conforti L, Adalbert R, Coleman MP (2007) Neuronal death: where does the end begin? Trends Neurosci 30:159-166.
23. Cookson MR (2005) The biochemistry of Parkinson's disease. Annu Rev Biochem 74:29-52.
24. Crosby AH, Proukakis C (2002) Is the transportation highway the right road for hereditary spastic paraplegia? Am J Hum Genet 71:1009-1016.
25. Dauer W, Przedborski S (2003) Parkinson's disease: mechanisms and models. Neuron 39:889-909.
26. DeBoer SR, You Y, Szodorai A, Kaminska A, Pigino G, Nwabuisi E, Wang B, Estrada-Hernandez T, Kins S, Brady ST, Morfini G (2008) Conventional kinesin holoenzymes are composed of heavy and light chain homodimers. Biochemistry 47:4535-4543.
27. Delcroix JD, Valletta J, Wu C, Howe CL, Lai CF, Cooper JD, Belichenko PV, Salehi A, Mobley WC (2004) Trafficking the NGF signal: implications for normal and degenerating neurons. Prog Brain Res 146:3-23. (Pubitemid 37541372)
28. De Vos KJ, Chapman AL, Tennant ME, Manser C, Tudor EL, Lau KF, Brownlees J, Ackerley S, Shaw PJ, McLoughlin DM, Shaw CE, Leigh PN, Miller CC, Grierson AJ (2007) Familial amyotrophic lateral sclerosis-linked SOD1 mutants perturb fast axonal transport to reduce axonal mitochondria content. Hum Mol Genet 16:2720-2728. (Pubitemid 350018514)
29. DiProspero NA, Chen EY, Charles V, Plomann M, Kordower JH, Tagle DA (2004) Early changes in Huntington's disease patient brains involve alterations in cytoskeletal and synaptic elements. J Neurocytol 33:517-533. (Pubitemid 40768575)
30. Djaldetti R, Lev N, Melamed E (2003) Neuroprotection in progressive brain disorders. Isr Med Assoc J 5:576-580.
31. Donelan MJ, Morfini G, Julyan R, Sommers S, Hays L, Kajio H, Briaud I, Easom RA, Molkentin JD, Brady ST, Rhodes CJ (2002) Ca2+- dependent dephosphorylation of kinesin heavy chain on beta-granules in pancreatic beta-cells. Implications for regulated beta-granule transport and insulin exocytosis. J Biol Chem 277:24232-24242. (Pubitemid 34951940)
32. Duda JE, Lee VM, Trojanowski JQ (2000) Neuropathology of synuclein aggregates. J Neurosci Res 61:121-127.
33. Edgar JM, McLaughlin M, Yool D, Zhang SC, Fowler JH, Montague P, Barrie JA, McCulloch MC, Duncan ID, Garbern J, Nave KA, Griffiths IR (2004) Oligodendroglial modulation of fast axonal transport in a mouse model of hereditary spastic paraplegia. J Cell Biol 166:121-131. (Pubitemid 38931922)
34. Edgar JM, McLaughlin M, Werner HB, McCulloch MC, Barrie JA, Brown A, Faichney AB, Snaidero N, Nave KA, Griffiths IR (2009) Early ultrastructural defects of axons and axon-glia junctions in mice lacking expression of Cnp1. Glia, in press.
35. Elluru RG, Bloom GS, Brady ST (1995) Fast axonal transport of kinesin in the rat visual system: functionality of the kinesin heavy chain isoforms. Mol Biol Cell 6:21-40.
36. Farrer MJ, Hulihan MM, Kachergus JM, Dächsel JC, Stoessl AJ, Grantier LL, Calne S, Calne DB, Lechevalier B, Chapon F, Tsuboi Y, Yamada T, Gutmann L, Elibol B, Bhatia KP, Wider C, Vilariño-Güell C, Ross OA, Brown LA, Castanedes-Casey M, et al. (2009) DCTN1 mutations in Perry syndrome. Nat Genet 41:163-165.
37. Ferreirinha F, Quattrini A, Pirozzi M, Valsecchi V, Dina G, Broccoli V, Auricchio A, Piemonte F, Tozzi G, Gaeta L, Casari G, Ballabio A, Rugarli EI (2004) Axonal degeneration in paraplegin-deficient mice is associated with abnormal mitochondria and impairment of axonal transport. J Clin Invest 113:231-242. (Pubitemid 38544208)
38. Fink JK (2006) Hereditary spastic paraplegia. Curr Neurol Neurosci Rep 6:65-76.
39. Fischer LR, Glass JD (2007) Axonal degeneration in motor neuron disease. Neurodegener Dis 4:431-442. (Pubitemid 47557285)
40. Fischer LR, Culver DG, Tennant P, Davis AA, Wang M, Castellano-Sanchez A, Khan J, Polak MA, Glass JD (2004) Amyotrophic lateral sclerosis is a distal axonopathy: evidence in mice and man. Exp Neurol 185:232-240. (Pubitemid 38084849)
41. Gamblin TC, Chen F, Zambrano A, Abraha A, Lagalwar S, Guillozet AL, Lu M, Fu Y, Garcia-Sierra F, LaPointe N, Miller R, Berry RW, Binder LI, Cryns VL (2003) Caspase cleavage of tau: linking amyloid and neurofibrillary tangles in Alzheimer's disease. Proc Natl Acad Sci U S A 100:10032-10037. (Pubitemid 37087063)
42. Garbern JY (2007) Pelizaeus-Merzbacher disease: genetic and cellular pathogenesis. Cell Mol Life Sci 64:50-65. (Pubitemid 46159445)
43. Garbern JY, Yool DA, Moore GJ, Wilds IB, Faulk MW, Klugmann M, Nave KA, Sistermans EA, van der Knaap MS, Bird TD, Shy ME, Kamholz JA, Griffiths IR (2002) Patients lacking the major CNS myelin protein, proteolipid protein 1, develop length-dependent axonal degeneration in the absence of demyelination and inflammation. Brain 125:551-561. (Pubitemid 34194410)
44. García-Sierra F, Ghoshal N, Quinn B, Berry RW, Binder LI (2003) Conformational changes and truncation of tau protein during tangle evolution in Alzheimer's disease. J Alzheimers Dis 5:65-77. (Pubitemid 36582767)
45. Gould TW, Buss RR, Vinsant S, Prevette D, Sun W, Knudson CM, Milligan CE, Oppenheim RW (2006) Complete dissociation of motor neuron death from motor dysfunction by Bax deletion in a mouse model of ALS. J Neurosci 26:8774-8786. (Pubitemid 44319413)
46. Griffiths I, Klugmann M, Anderson T, Yool D, Thomson C, Schwab MH, Schneider A, Zimmermann F, McCulloch M, Nadon N, Nave KA (1998) Axonal swellings and degeneration in mice lacking the major proteolipid of myelin. Science 280:1610-1613. (Pubitemid 28278256)
47. Guillozet-Bongaarts AL, Garcia-Sierra F, Reynolds MR, Horowitz PM, Fu Y, Wang T, Cahill ME, Bigio EH, Berry RW, Binder LI (2005) Tau truncation during neurofibrillary tangle evolution in Alzheimer's disease. Neurobiol Aging 26:1015-1022. (Pubitemid 40312665)
48. Gunawardena S, Her LS, Brusch RG, Laymon RA, Niesman IR, Gordesky- Gold B, Sintasath L, Bonini NM, Goldstein LS (2003) Disruption of axonal transport by loss of huntingtin or expression of pathogenic polyQ proteins in Drosophila. Neuron 40:25-40. (Pubitemid 37222462)
49. Gurney ME, Pu H, Chiu AY, Dal Canto MC, Polchow CY, Alexander DD, Caliendo J, Hentati A, Kwon YW, Deng HX, Chen W, Zhai P, Sufit RL, Siddique T (1994) Motor neuron degeneration in mice that express human Cu, Zn superoxide dismutase mutation. Science 264:1772-1775.
50. Hafezparast M, Klocke R, Ruhrberg C, Marquardt A, Ahmad-Annuar A, Bowen S, Lalli G, Witherden AS, Hummerich H, Nicholson S, Morgan PJ, Oozageer R, Priestley JV, Averill S, King VR, Ball S, Peters J, Toda T, Yamamoto A, Hiraoka Y, et al. (2003) Mutations in dynein link motor neuron degeneration to defects in retrograde transport. Science 300:808-812. (Pubitemid 36532118)
51. Hardy J, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297:353-356.
52. Her LS, Goldstein LS (2008) Enhanced sensitivity of striatal neurons to axonal transport defects induced by mutant huntingtin. J Neurosci 28:13662-13672.
53. Hirokawa N, Takemura R (2003) Biochemical and molecular characterization of diseases linked to motor proteins. Trends Biochem Sci 28: 558-565. (Pubitemid 38366282)
54. Hollenbeck PJ (1990) Kinesin heavy and light chains are phosphorylated in vivo in neurons. J Cell Biol 115:390a.
55. Holzbaur EL (2004) Motor neurons rely on motor proteins. Trends Cell Biol 14:233-240.
56. Horowitz PM, Patterson KR, Guillozet-Bongaarts AL, Reynolds MR, Carroll CA, Weintraub ST, Bennett DA, Cryns VL, Berry RW, Binder LI (2004) Early N-terminal changes and caspase-6 cleavage of tau in Alzheimer's disease. J Neurosci 24:7895-7902.
57. James PA, Talbot K (2006) The molecular genetics of non-ALS motor neuron diseases. Biochim Biophys Acta 1762:986-1000. (Pubitemid 44750576)
58. Jeganathan S, von Bergen M, Brutlach H, Steinhoff HJ, Mandelkow E (2006) Global hairpin folding of tau in solution. Biochemistry 45:2283-2293. (Pubitemid 43271328)
59. Kaul S, Kanthasamy A, Kitazawa M, Anantharam V, Kanthasamy AG (2003) Caspase-3 dependent proteolytic activation of protein kinase C delta mediates and regulates 1-methyl-4-phenylpyridinium (MPP+)-induced apoptotic cell death in dopaminergic cells: relevance to oxidative stress in dopaminergic degeneration. Eur J Neurosci 18:1387-1401. (Pubitemid 37215094)
60. Klein WL, Stine WB Jr, Teplow DB (2004) Small assemblies of unmodified amyloid beta-protein are the proximate neurotoxin in Alzheimer's disease. Neurobiol Aging 25:569-580.
61. Klugmann M, Schwab MH, Pühlhofer A, Schneider A, Zimmermann F, Griffiths IR, Nave KA (1997) Assembly of CNS myelin in the absence of proteolipid protein. Neuron 18:59-70. (Pubitemid 27053830)
62. Kwiatkowski TJ Jr, Bosco DA, Leclerc AL, Tamrazian E, Vanderburg CR, Russ C, Davis A, Gilchrist J, Kasarskis EJ, Munsat T, Valdmanis P, Rouleau GA, Hosler BA, Cortelli P, de Jong PJ, Yoshinaga Y, Haines JL, Pericak-Vance MA, Yan J, Ticozzi N, et al. (2009) Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science 323:1205-1208.
63. Lagier-Tourenne C, Cleveland DW (2009) Rethinking ALS: the FUS about TDP-43. Cell 136:1001-1004.
64. Landers JE, Melki J, Meininger V, Glass JD, van den Berg LH, van Es MA, Sapp PC, van Vught PW, McKenna-Yasek DM, Blauw HM, Cho TJ, Polak M, Shi L, Wills AM, Broom WJ, Ticozzi N, Silani V, Ozoguz A, Rodriguez- Leyva I, Veldink JH, et al. (2009) Reduced expression of the kinesinassociated protein 3 (KIFAP3) gene increases survival in sporadic amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A 106:9004-9009.
65. Lapointe NE, Morfini G, Pigino G, Gaisina IN, Kozikowski AP, Binder LI, Brady ST (2009) The amino terminus of tau inhibits kinesin-dependent axonal transport: implications for filament toxicity. J Neurosci Res 97:440-451.
66. Lappe-Siefke C, Goebbels S, Gravel M, Nicksch E, Lee J, Braun PE, Griffiths IR, Nave KA (2003) Disruption of Cnp1 uncouples oligodendroglial functions in axonal support and myelination. Nat Genet 33:366-374. (Pubitemid 36278853)
67. Lazarov O, Morfini GA, Pigino G, Gadadhar A, Chen X, Robinson J, Ho H, Brady ST, Sisodia SS (2007) Impairments in fast axonal transport and motor neuron deficits in transgenic mice expressing familial Alzheimer's disease-linked mutant presenilin 1. J Neurosci 27:7011-7020. (Pubitemid 47015908)
68. Lee WC, Yoshihara M, Littleton JT (2004) Cytoplasmic aggregates trap polyglutamine-containing proteins and block axonal transport in a Drosophila model of Huntington's disease. Proc Natl Acad Sci U S A 101:3224-3229.
69. Leopold PL, McDowall AW, Pfister KK, Bloom GS, Brady ST (1992) Association of kinesin with characterized membrane-bounded organelles. Cell Motil Cytoskeleton 23:19-33.
70. Li H, Li SH, Yu ZX, Shelbourne P, Li XJ (2001) Huntingtin aggregateassociated axonal degeneration is an early pathological event in Huntington's disease mice. J Neurosci 21:8473-8481. (Pubitemid 33051446)
71. Li SH, Li XJ (2004) Huntingtin and its role in neuronal degeneration. Neuroscientist 10:467-475.
72. Liévens JC, Woodman B, Mahal A, Bates GP (2002) Abnormal phosphorylation of synapsin I predicts a neuronal transmission impairment in the R6/2 Huntington's disease transgenic mice. Mol Cell Neurosci 20:638-648.
73. Luo MH, Tse SW, Memmott J, Andreadis A (2004) Novel isoforms of tau that lack the microtubule-binding domain. J Neurochem 90:340-351. (Pubitemid 38938220)
74. Mattson MP (2004) Pathways towards and away from Alzheimer's disease. Nature 430:631-639. (Pubitemid 39061671)
75. Mattson MP, Magnus T (2006) Ageing and neuronal vulnerability. Nat Rev Neurosci 7:278-294.
76. Moreno H, Yu E, Pigino G, Hernandez AI, Kim N, Moreira JE, Sugimori M, Llinás RR (2009) Synaptic transmission block by presynaptic injection of oligomeric amyloid beta. Proc Natl Acad Sci U S A 106:5901-5906.
77. Morfini G, Szebenyi G, Richards B, Brady ST (2001) Regulation of kinesin: implications for neuronal development. Dev Neurosci 23:364-376. (Pubitemid 34045231)
78. Morfini G, Szebenyi G, Elluru R, Ratner N, Brady ST (2002a) Glycogen synthase kinase 3 phosphorylates kinesin light chains and negatively regulates kinesin-based motility. EMBO J 23:281-293. (Pubitemid 34137290)
79. Morfini G, Pigino G, Beffert U, Busciglio J, Brady ST (2002b) Fast axonal transport misregulation and Alzheimer's disease. Neuromolecular Med 2:89-99. (Pubitemid 37012498)
80. Morfini G, Szebenyi G, Brown H, Pant HC, Pigino G, DeBoer S, Beffert U, Brady ST (2004) A novel CDK5-dependent pathway for regulating GSK3 activity and kinesin-driven motility in neurons. EMBO J 23:2235-2245. (Pubitemid 38833233)
81. Morfini G, Pigino G, Brady ST (2005) Polyglutamine expansion diseases: failing to deliver. Trends Mol Med 11:64-70. (Pubitemid 40193484)
82. Morfini GA, Stenoien, DL, Brady, ST (2006a) Axonal transport. In: Basic neurochemistry, Ed 7 (Siegel G, Albers RW, Brady S, Price D, eds), pp 485-502. Burlington, MA: Elsevier Academic.
83. Morfini G, Pigino G, Szebenyi G, You Y, Pollema S, Brady ST (2006b) JNK mediates pathogenic effects of polyglutamine-expanded androgen receptor on fast axonal transport. Nat Neurosci 9:907-916. (Pubitemid 43980505)
84. Morfini G, Pigino G, Brady ST (2007a) Approaches to kinesin-1 phosphorylation. Methods Mol Biol 392:51-69.
85. Morfini G, Pigino G, Mizuno N, Kikkawa M, Brady ST (2007b) Tau binding to microtubules does not directly affect microtubule-based vesicle motility. J Neurosci Res 85:2620-2630. (Pubitemid 47344564)
86. Morfini G, Pigino G, Opalach K, Serulle Y, Moreira JE, Sugimori M, Llinás RR, Brady ST (2007c) 1-Methyl-4-phenylpyridinium affects fast axonal transport by activation of caspase and protein kinase C. Proc Natl Acad Sci U S A 104:2442-2447.
87. Morfini GA, You YM, Pollema SL, Kaminska A, Liu K, Yoshioka K, Björkblom B, Coffey ET, Bagnato C, Han D, Huang CF, Banker G, Pigino G, Brady ST (2009) Pathogenic huntingtin inhibits fast axonal transport by activating JNK3 and phosphorylating kinesin. Nat Neurosci 12:864-871.
88. Morsch R, Simon W, Coleman PD (1999) Neurons may live for decades with neurofibrillary tangles. J Neuropathol Exp Neurol 58:188-197. (Pubitemid 29088942)
89. Papasozomenos SC, Binder LI (1987) Phosphorylation determined two distinct species of tau in the central nervous system. Cell Motil Cytoskeleton 8:210-226.
90. Pasinelli P, Brown RH (2006) Molecular biology of amyotrophic lateral sclerosis: insights from genetics. Nat Rev Neurosci 7:710-723. (Pubitemid 44267495)
91. Pigino G, Pelsman A, Mori H, Busciglio J (2001) Presenilin-1 mutations reduce cytoskeletal association, deregulate neurite growth, and potentiate neuronal dystrophy and tau phosphorylation. J Neurosci 21:834-842. (Pubitemid 32163124)
92. Pigino G, Morfini G, Pelsman A, Mattson MP, Brady ST, Busciglio J (2003) Alzheimer's presenilin 1 mutations impair kinesin-based axonal transport. J Neurosci 23:4499-4508. (Pubitemid 36706180)
93. Pigino G, Morfini G, Atagi Y, Deshpande A, Yu C, Jungbauer L, LaDu M, Busciglio J, Brady S (2009) Disruption of fast axonal transport is a pathogenic mechanism for intraneuronal amyloid beta. Proc Natl Acad Sci U S A 106:5907-5912.
94. Price DL, Tanzi RE, Borchelt DR, Sisodia SS (1998) Alzheimer's disease: genetic studies and transgenic models. Annu Rev Genet 32:461-493. (Pubitemid 29045321)
95. Price DL, Wong PC, Markowska AL, Lee MK, Thinakaren G, Cleveland DW, Sisodia SS, Borchelt DR (2000) The value of transgenic models for the study of neurodegenerative diseases. Ann N Y Acad Sci 920:179-191. (Pubitemid 32056567)
96. Puls I, Jonnakuty C, LaMonte BH, Holzbaur EL, Tokito M, Mann E, Floeter MK, Bidus K, Drayna D, Oh SJ, Brown RH Jr, Ludlow CL, Fischbeck KH (2003) Mutant dynactin in motor neuron disease. Nat Genet 33: 455-456. (Pubitemid 36390002)
97. Puls I, Oh SJ, Sumner CJ, Wallace KE, Floeter MK, Mann EA, Kennedy WR, Wendelschafer-Crabb G, Vortmeyer A, Powers R, Finnegan K, Holzbaur EL, Fischbeck KH, Ludlow CL (2005) Distal spinal and bulbar muscular atrophy caused by dynactin mutation. Ann Neurol 57:687-694. (Pubitemid 40628857)
98. Reid E, Kloos M, Ashley-Koch A, Hughes L, Bevan S, Svenson IK, Graham FL, Gaskell PC, Dearlove A, Pericak-Vance MA, Rubinsztein DC, Marchuk DA (2002) A kinesin heavy chain (KIF5A) mutation in hereditary spastic paraplegia (SPG10). Am J Hum Genet 71:1189-1194. (Pubitemid 35305237)
99. Rosenbluth J, Nave KA, Mierzwa A, Schiff R (2006) Subtle myelin defects in PLP-null mice. Glia 54:172-182. (Pubitemid 44230854)
100. Roy S, Zhang B, Lee VM, Trojanowski JQ (2005) Axonal transport defects: a common theme in neurodegenerative diseases. Acta Neuropathol 109:5-13. (Pubitemid 40287785)
101. Rutherford NJ, Zhang YJ, Baker M, Gass JM, Finch NA, Xu YF, Stewart H, Kelley BJ, Kuntz K, Crook RJ, Sreedharan J, Vance C, Sorenson E, Lippa C, Bigio EH, Geschwind DH, Knopman DS, Mitsumoto H, Petersen RC, Cashman NR, et al. (2008) Novel mutations in TARDBP (TDP-43) in patients with familial amyotrophic lateral sclerosis. PLoS Genet 4: e1000193.
102. Salinas S, Proukakis C, Crosby A, Warner TT (2008) Hereditary spastic paraplegia: clinical features and pathogenetic mechanisms. Lancet Neurol 7:1127-1138.
103. Saugier-Veber P, Munnich A, Bonneau D, Rozet JM, Le Merrer M, Gil R, Boespflug-Tanguy O (1994) X-linked spastic paraplegia and Pelizaeus- Merzbacher disease are allelic disorders at the proteolipid protein locus. Nat Genet 6:257-262. (Pubitemid 24188622)
104. Serulle Y, Morfini G, Pigino G, Moreira JE, Sugimori M, Brady ST, Llinás RR (2007) 1-Methyl-4-phenylpyridinium induces synaptic dysfunction through a pathway involving caspase and PKC{delta} enzymatic activities. Proc Natl Acad Sci U S A 104:2437-2441. (Pubitemid 46391415)
105. Sieradzan KA, Mann DM (2001) The selective vulnerability of nerve cells in Huntington's disease. Neuropathol Appl Neurobiol 27:1-21. (Pubitemid 32291184)
106. Solowska JM, Morfini G, Falnikar A, Himes BT, Brady ST, Huang D, Baas PW (2008) Quantitative and functional analyses of spastin in the nervous system: implications for hereditary spastic paraplegia. J Neurosci 28: 2147-2157. (Pubitemid 351317638)
107. Spillantini MG, Goedert M (2000) The alpha-synucleinopathies: Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy. Ann N Y Acad Sci 920:16-27. (Pubitemid 32056547)
108. Stenoien DL, Brady ST (1997) Immunochemical analysis of kinesin light chain function. Mol Biol Cell 8:675-689.
109. Sugars KL, Rubinsztein DC (2003) Transcriptional abnormalities in Huntington disease. Trends Genet 19:233-238.
110. Susalka SJ, Pfister KK (2000) Cytoplasmic dynein subunit heterogeneity: implications for axonal transport. J Neurocytol 29:819-829.
111. Szebenyi G, Morfini GA, Babcock A, Gould M, Selkoe K, Stenoien DL, Young M, Faber PW, MacDonald ME, McPhaul MJ, Brady ST (2003) Neuropathogenic forms of huntingtin and androgen receptor inhibit fast axonal transport. Neuron 40:41-52. (Pubitemid 37229083)
112. Tarrade A, Fassier C, Courageot S, Charvin D, Vitte J, Peris L, Thorel A, Mouisel E, Fonknechten N, Roblot N, Seilhean D, Diérich A, Hauw JJ, Melki J (2006) A mutation of spastin is responsible for swellings and impairment of transport in a region of axon characterized by changes in microtubule composition. Hum Mol Genet 15:3544-3558. (Pubitemid 44884122)
113. Tortarolo M, Veglianese P, Calvaresi N, Botturi A, Rossi C, Giorgini A, Migheli A, Bendotti C (2003) Persistent activation of p38 mitogen-activated protein kinase in a mouse model of familial amyotrophic lateral sclerosis correlates with disease progression. Mol Cell Neurosci 23:180-192. (Pubitemid 36703155)
114. Turmel H, Hartmann A, Parain K, Douhou A, Srinivasan A, Agid Y, Hirsch EC (2001) Caspase-3 activation in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated mice. Mov Disord 16:185-189.
115. Viswanath V, Wu Y, Boonplueang R, Chen S, Stevenson FF, Yantiri F, Yang L, Beal MF, Andersen JK (2001) Caspase-9 activation results in downstream caspase-8 activation and bid cleavage in 1-methyl-4-phenyl- 1,2,3,6- tetrahydropyridine-induced Parkinson's disease. J Neurosci 21:9519-9528.
116. Wagey RT, Krieger C (1998) Abnormalities of protein kinases in neurodegenerative diseases. Prog Drug Res 51:133-183. (Pubitemid 28511543)
117. Wagner MC, Pfister KK, Bloom GS, Brady ST (1989) Copurification of kinesin polypeptides with microtubule-stimulated Mg-ATPase activity and kinetic analysis of enzymatic processes. Cell Motil Cytoskeleton 12: 195-215.
118. Waldmeier P, Bozyczko-Coyne D, Williams M, Vaught JL (2006) Recent clinical failures in Parkinson's disease with apoptosis inhibitors underline the need for a paradigm shift in drug discovery for neurodegenerative diseases. Biochem Pharmacol 72:1197-1206. (Pubitemid 44604283)
119. Wang JZ, Grundke-Iqbal I, Iqbal K (2007) Kinases and phosphatases and tau sites involved in Alzheimer neurofibrillary degeneration. Eur J Neurosci 25:59-68. (Pubitemid 46098893)
120. Warita H, Itoyama Y, Abe K (1999) Selective impairment of fast anterograde axonal transport in the peripheral nerves of asymptomatic transgenic mice with a G93A mutant SOD1 gene. Brain Res 819:120-131. (Pubitemid 29225463)
121. Williamson TL, Cleveland DW (1999) Slowing of axonal transport is a very early event in the toxicity of ALS-linked SOD1 mutants to motor neurons. Nat Neurosci 2:50-56.
122. Wishart TM, Parson SH, Gillingwater TH (2006) Synaptic vulnerability in neurodegenerative disease. J Neuropathol Exp Neurol 65:733-739.
123. Witt A, Brady ST (2000) Unwrapping new layers of complexity in axon/glial relationships. Glia 29:112-117. (Pubitemid 30044504)
124. Wong PC, Cai H, Borchelt DR, Price DL (2002) Genetically engineered mouse models of neurodegenerative diseases. Nat Neurosci 5:633-639. (Pubitemid 34742978)
125. Zhang F, Ström AL, Fukada K, Lee S, Hayward LJ, Zhu H (2007) Interaction between familial amyotrophic lateral sclerosis (ALS)-linked SOD1 mutants and the dynein complex. J Biol Chem 282:16691-16699. (Pubitemid 47100405)